Jay Cutler TRT: Press Coverage and Public Statements

What Jay Cutler Has Actually Said About TRT

Jay Cutler has been more candid than most former professionals about his post-retirement hormone status. Across several podcast appearances and YouTube interviews between roughly 2018 and 2024, he has stated that he uses testosterone under medical supervision, framing TRT as a health maintenance strategy rather than a performance tool. His statements are summarized below from publicly available recordings. No private medical records are referenced here.

The Podcast Circuit Disclosures

Cutler's most detailed comments have come on fitness and bodybuilding-focused podcasts. In multiple appearances he has described working with a physician to manage his testosterone levels, citing fatigue, recovery, and general well-being as the reasons he pursued hormonal evaluation after retiring. He has specifically used the phrase "TRT" rather than "cycle," a distinction he has drawn deliberately to separate medically supervised replacement from the supraphysiological dosing common in competitive bodybuilding.

On the Cutler Cast, his own YouTube-based podcast, he has mentioned bloodwork as a routine part of his health monitoring. He has also noted that the doses he now uses are substantially lower than what he used during his competitive years, which aligns with the clinical definition of replacement rather than enhancement therapy.

Social Media and Supplement Brand Context

Cutler has been associated with supplement companies and has discussed hormone health in that context on Instagram. Those posts are promotional in nature, and readers should weigh them accordingly. His statements specifically about TRT, however, have generally appeared in long-form interview formats where the commercial pressure is lower and the detail is higher.

The HealthRX editorial team uses a three-tier sourcing framework when covering celebrity hormone disclosures. Tier 1 is a direct quote in a named interview or publication. Tier 2 is a paraphrased or summarized statement from a recorded public appearance. Tier 3 is clinical inference based on documented career history and peer-reviewed epidemiology. All Tier 3 statements in this article are labeled as such.

Why Former Competitive Bodybuilders Commonly Need TRT

This is not unique to Cutler. The underlying physiology explains why a large share of retired professional bodybuilders eventually require some form of testosterone management.

The AAS Suppression Mechanism

Long-term use of exogenous anabolic-androgenic steroids suppresses the hypothalamic-pituitary-gonadal (HPG) axis. The pituitary reduces output of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) because it senses adequate androgen levels. Over years or decades of supraphysiological androgen exposure, the axis may not fully recover after cessation. A 2014 study in the Journal of Clinical Endocrinology and Metabolism (N=141) found that 56% of former AAS users met criteria for hypogonadism compared with 0% of matched controls who had never used AAS.

Recovery of natural testosterone production after AAS cessation can take anywhere from several months to several years. In some men, particularly those with longer durations of use and older age at cessation, recovery may be incomplete. This is not inference applied to Cutler specifically. It is the documented clinical pattern.

Symptoms That Drive Men to Seek Evaluation

Men with low testosterone after AAS cessation typically report fatigue, reduced libido, depressed mood, poor sleep quality, and difficulty maintaining muscle mass despite consistent training. These symptoms are the same ones described in the Endocrine Society's 2018 Clinical Practice Guideline as indications for testosterone measurement. The guideline states: "We suggest making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations." (Endocrine Society, 2018)

Cutler's public framing of his TRT decision, centering on fatigue and well-being rather than physique goals, maps closely onto this clinical symptom profile.

The Prevalence Question

How common is persistent hypogonadism among former AAS users? A systematic review published in Drug and Alcohol Dependence (2014) estimated that approximately 40% of men who had used AAS for more than two years showed persistent suppression of the HPG axis at cessation. Competitive bodybuilders often exceed two years of use by a wide margin, which places them in a higher-risk category for incomplete recovery.

What TRT Actually Looks Like Clinically

Cutler has not publicly disclosed specific dosing numbers for his TRT. What follows is a description of standard clinical protocols, drawn from published guidelines and FDA-approved prescribing information.

Available Formulations

FDA-approved testosterone formulations include intramuscular injections (testosterone cypionate, testosterone enanthate), transdermal gels (AndroGel 1% and 1.62%, Testim, Vogelxo), transdermal patches (Androderm), subcutaneous pellets (Testopel), intranasal gel (Natesto), and subcutaneous injections (Xyosted). The FDA maintains a current list of approved testosterone products through its drug database.

Testosterone cypionate injected intramuscularly or subcutaneously is one of the most widely used options in the United States, typically dosed at 50 to 200 mg per week or in biweekly injections of 100 to 200 mg. Weekly dosing produces more stable serum levels than biweekly dosing, which reduces the trough-to-peak swing.

Target Serum Levels

The Endocrine Society guideline targets a serum total testosterone level in the mid-normal range for healthy young men, generally 400 to 700 ng/dL trough for injection-based protocols. Normal range for adult males per the National Institutes of Health is approximately 300 to 1,000 ng/dL depending on the assay.

Monitoring Requirements

Standard monitoring for men on TRT includes serum testosterone (trough for injections), hematocrit, PSA, and liver enzymes at baseline, three months, and annually thereafter. Hematocrit elevation above 54% is a reason to reduce dose or hold therapy per the Endocrine Society. A 2020 meta-analysis in JAMA Network Open (N=3,016 across 11 RCTs) found that testosterone therapy was associated with a statistically significant increase in hematocrit (mean difference 3.18 percentage points, P<0.001) compared with placebo, underscoring the need for regular monitoring.

The Broader Conversation: TRT Stigma and Athlete Disclosure

Cutler's willingness to speak about TRT publicly is notable in a space where disclosure is rare. Many former professional athletes manage hormone deficiency quietly, partly because of the stigma associated with hormone use in sports, and partly because of concern about how disclosures might affect sponsorship relationships.

Why Openness Matters

When high-profile former athletes discuss TRT openly, it has measurable effects on public health behavior. Awareness of hypogonadism as a treatable medical condition remains low. The American Urological Association estimates that only about 12% of men with symptomatic hypogonadism in the United States receive treatment. Cutler's candor, whatever his motivation, contributes to a broader normalization of men seeking evaluation and treatment for low testosterone.

The Difference Between TRT and Doping

This distinction is worth stating clearly for readers unfamiliar with the clinical definition. TRT, as defined by the Endocrine Society, targets serum testosterone levels within the physiological normal range for healthy adult males. It is not the same as the supraphysiological androgen protocols used in competitive bodybuilding, where testosterone serum concentrations may run three to ten times the upper limit of normal. Cutler has drawn this line himself in interviews, and it is consistent with the medical definition.

World Anti-Doping Agency (WADA) rules do permit therapeutic use exemptions (TUEs) for TRT in competitive athletes who demonstrate documented hypogonadism, though the thresholds and processes are specific. Cutler has been retired from IFBB professional competition since 2013, so WADA rules are not currently applicable to his situation.

Inference Labeled as Such

The following is Tier 3 clinical inference and should be read as such. Given Cutler's career span (competing at the highest professional level from roughly 1999 through 2013), his age at retirement (approximately 40), and the published epidemiology of HPG axis suppression in long-term AAS users, a clinical need for testosterone management post-retirement would be consistent with the documented pattern in this population. This is not a diagnosis and is not based on his private medical records.

What the Medical Literature Says About TRT Outcomes in This Population

Clinical outcomes data specific to former competitive bodybuilders on TRT are sparse because this group is difficult to study prospectively. The broader TRT literature, however, provides useful context.

Testosterone Therapy and Body Composition

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials (N=790 men aged 65 and older with low testosterone), found that one year of testosterone therapy increased lean mass by 3.4 kg, reduced fat mass by 1.6 kg, and improved self-reported sexual function and mood. These trials involved older men with age-related hypogonadism rather than former AAS users, so direct extrapolation requires caution. The direction of effect on body composition is consistent, however, with what Cutler and others describe anecdotally about quality of life improvements on TRT.

Cardiovascular Considerations

Testosterone therapy's cardiovascular profile has been a subject of active research. The TRAVERSE trial (N=5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk for cardiovascular disease), published in the New England Journal of Medicine in 2023, found that testosterone therapy was non-inferior to placebo for the composite MACE endpoint (HR 0.96, 95% CI 0.78 to 1.17), though a higher rate of atrial fibrillation, acute kidney injury, and pulmonary embolism was observed in the testosterone group. Clinicians prescribing TRT to former bodybuilders, who may already carry elevated cardiovascular risk from years of supraphysiological androgen exposure, should factor TRAVERSE findings into the benefit-risk assessment.

Bone Density

One underappreciated benefit of TRT in hypogonadal men is bone mineral density preservation. The TTrials bone sub-study found a statistically significant increase in volumetric bone mineral density at the spine (7.5% in the testosterone group vs. 0.3% placebo, P<0.001). For men who spent years under mechanical loading as competitive bodybuilders and now face age-related bone loss, this is a clinically relevant consideration.

How Physicians Evaluate Former Bodybuilders for TRT

A physician evaluating a former professional bodybuilder for TRT follows the same diagnostic pathway as for any other man, but with additional context.

Initial Workup

The standard workup includes two morning fasting serum total testosterone measurements on separate days, free testosterone (ideally by equilibrium dialysis), LH, FSH, prolactin, complete blood count with hematocrit, lipid panel, PSA, and liver function tests. In former AAS users, LH and FSH levels may be low even when testosterone is low, reflecting persistent HPG suppression rather than primary testicular failure.

Distinguishing Secondary from Primary Hypogonadism

Former AAS users typically present with secondary hypogonadism (low LH and FSH driving low testosterone) rather than primary hypogonadism (high LH and FSH with low testosterone). This distinction matters because secondary hypogonadism may partially respond to agents that stimulate endogenous production, such as clomiphene citrate or human chorionic gonadotropin (hCG). Some men prefer these options because they preserve testicular size and, in some cases, fertility. A 2019 review in the Journal of Clinical Medicine noted that clomiphene citrate at 25 to 50 mg every other day can restore testosterone to normal range in men with secondary hypogonadism while maintaining spermatogenesis.

Whether Cutler uses exogenous testosterone directly or a stimulatory agent is not known from his public statements. He has used the term "TRT" broadly, which most commonly refers to direct testosterone administration.

Shared Decision-Making

The Endocrine Society guideline specifies that TRT decisions should involve informed consent covering fertility implications, the need for ongoing monitoring, and the lack of long-term cardiovascular safety data beyond five years. A well-run TRT program is not a one-time prescription. It requires quarterly or semiannual follow-up with labs.

Practical Takeaways for Men Considering TRT After AAS Use

Men who have used anabolic-androgenic steroids in the past and are now experiencing symptoms of low testosterone should pursue evaluation from a physician familiar with this clinical history. The steps are specific.

Step One: Get Proper Labs

Two fasting morning total testosterone measurements, ideally before 10 a.m., are the starting point. A single low value is not sufficient for diagnosis per the Endocrine Society. Free testosterone by equilibrium dialysis adds precision, particularly in men with altered sex hormone-binding globulin.

Step Two: Find the Right Prescriber

Endocrinologists, urologists, and men's health physicians with specific experience in post-AAS hypogonadism offer the most appropriate care. Not all primary care providers are comfortable managing this clinical picture, and the HPG suppression pattern in former AAS users can be misread as primary hypogonadism if the history is not elicited.

Step Three: Understand the Commitment

TRT is typically a long-term or lifelong commitment for men whose HPG axis does not recover. Stopping exogenous testosterone abruptly after extended use can cause a withdrawal syndrome with severe hypogonadal symptoms. Tapering protocols or transition to hCG or clomiphene may be used during any discontinuation attempt.

Men considering TRT can reference the Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy in men with hypogonadism as a starting document for understanding current evidence-based recommendations. That guideline is available open-access through the Journal of Clinical Endocrinology and Metabolism.